Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Bal

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2021
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple MyelomaLuciano J Costa, Saurabh Chhabra, Eva Medvedova, et al.
American Journal of Hematology|June 22, 2022
Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapySusan Bal, Binod Dhakal, Rebecca W Silbermann, et al.
British Journal of Cancer|June 7, 2024
Anthropometric traits and risk of multiple myeloma: differences by race, sex and diagnostic clinical featuresKevin D Arnold, Krystle L Ong, Gayathri Ravi, et al.
Bone Marrow Transplantation|November 21, 2021
A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patientsCarlyn Rose Tan, Noel Estrada-Merly, Heather Landau, et al.
American Journal of Hematology|May 20, 2026
Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World AnalysisMurali Janakiram, Carlyn R Tan, Hira Mian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2026
Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living GuidelineLisa K Hicks, Hans J Messersmith, Samer Al Hadidi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 23, 2020
Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple MyelomaSusan Bal, Heather J Landau, Gunjan L Shah, et al.
Blood|June 3, 2026
Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myelomaSusan Bal, Myo Htut, Omar Nadeem, et al.
Blood Advances|February 24, 2026
Early Mortality with Bispecific Antibody Therapy in RRMM: An IMWG Immunotherapy Database Real-World AnalysisCarlyn Rose Tan, Saad Z Usmani, Andriy Derkach, et al.
Leukemia|January 27, 2025
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myelomaLuciano J Costa, Rahul Banerjee, Hira Mian, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2021
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple MyelomaLuciano J Costa, Saurabh Chhabra, Eva Medvedova, et al.
American Journal of Hematology|June 22, 2022
Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapySusan Bal, Binod Dhakal, Rebecca W Silbermann, et al.
British Journal of Cancer|June 7, 2024
Anthropometric traits and risk of multiple myeloma: differences by race, sex and diagnostic clinical featuresKevin D Arnold, Krystle L Ong, Gayathri Ravi, et al.
Bone Marrow Transplantation|November 21, 2021
A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patientsCarlyn Rose Tan, Noel Estrada-Merly, Heather Landau, et al.
American Journal of Hematology|May 20, 2026
Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World AnalysisMurali Janakiram, Carlyn R Tan, Hira Mian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2026
Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living GuidelineLisa K Hicks, Hans J Messersmith, Samer Al Hadidi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 23, 2020
Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple MyelomaSusan Bal, Heather J Landau, Gunjan L Shah, et al.
Blood|June 3, 2026
Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myelomaSusan Bal, Myo Htut, Omar Nadeem, et al.
Blood Advances|February 24, 2026
Early Mortality with Bispecific Antibody Therapy in RRMM: An IMWG Immunotherapy Database Real-World AnalysisCarlyn Rose Tan, Saad Z Usmani, Andriy Derkach, et al.
Leukemia|January 27, 2025
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myelomaLuciano J Costa, Rahul Banerjee, Hira Mian, et al.
Pageof 7